Literature DB >> 2847352

Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells--inhibition of thrombomodulin-dependent protein C activation.

R Cariou1, G Tobelem, S Bellucci, J Soria, C Soria, J Maclouf, J Caen.   

Abstract

We have investigated the effect of purified immunoglobulin G (IgG) on endothelial cell functions in 16 patients with lupus anticoagulant, 9 of whom had systemic lupus erythematosus (SLE). Spontaneous or thrombin-stimulated secretion of prostacyclin (PGI2) by cultured human endothelial cells from umbilical cord vein (HUVEC) was not inhibited by the patient's IgG. Nor was spontaneous release of tissue plasminogen activator (t-PA) or of its inhibitor (PAI) modified in the presence of patient's IgG. The rate of activation of purified protein C (PC) by HUVEC in the presence of thrombin was significantly lowered by patient's IgG or Fab' fragment (inhibition of 43%). Neutralization of this effect was obtained by incubation of a greater quantity of phospholipids (phosphatidylcholine, phosphatidylserine) with the patient's IgG. Activation of PC was also performed using purified rabbit thrombomodulin (TM) and a similar inhibition of the patient IgG was observed (inhibition of 48%) but the activation of Gla-domainless PC was not modified.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2847352

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  21 in total

Review 1.  Diagnosis and management of inherited and acquired thrombophilias.

Authors:  F A Spencer; R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 2.  Clinical trials for the antiphospholipid syndrome.

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

Review 3.  The antiphospholipid syndrome and atherosclerosis: clue to pathogenesis.

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

Review 4.  The antiphospholipid antibody dilemma.

Authors:  R H Derksen; P Hasselaar; J D Oosting; P G De Groot
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

5.  Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset.

Authors:  N Nakamura; T Ban; K Yamaji; Y Yoneda; Y Wada
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

6.  Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro.

Authors:  D A Tsakiris; M L Yasikoff; F Wolf; G A Marbet
Journal:  Ann Hematol       Date:  1995-10       Impact factor: 3.673

Review 7.  Antiphospholipid antibodies and the antiphospholipid syndrome.

Authors:  E N Harris; S S Pierangeli
Journal:  Springer Semin Immunopathol       Date:  1994

Review 8.  The antiphospholipid syndrome. Diagnosis, management, and pathogenesis.

Authors:  E N Harris
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

9.  Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

Authors:  R Simantov; J M LaSala; S K Lo; A E Gharavi; L R Sammaritano; J E Salmon; R L Silverstein
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

Review 10.  Antibodies to serine proteases in the antiphospholipid syndrome.

Authors:  Pojen P Chen; Ian Giles
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.